Publication | Closed Access
Treatment of cytomegalovirus pneumonia in heart transplant recipients with 9(1,3-dihydroxy-2-proproxymethyl)-guanine (DHPG).
21
Citations
0
References
1988
Year
Translational MedicineTransplantationAntiviral CompoundNeurovirologyHeart Transplant RecipientsTransplantation MedicineAntiviral Drug DevelopmentAntiviral TherapyVirologyBiopsy-proved Cmv PneumoniaAntiviral DrugImmunotherapyMedicineClinical EfficacyCmv PneumoniaHeart TransplantationCytomegalovirus Pneumonia
Cytomegalovirus (CMV) infection is a frequent cause of serious illness in heart transplant patients and may cause life-threatening pneumonia, with a reported mortality of greater than 50%. We investigated the clinical efficacy of a new antiviral agent, 9(1,3-dihydroxy-2-proproxymethyl)-guanine (DHPG) in the treatment of CMV pneumonia in heart transplant patients. Four of these patients with biopsy-proved CMV pneumonia were treated with DHPG, with resolution of pneumonia and no relapse at a mean follow-up period of 21 weeks. DHPG may be useful in the treatment of CMV pneumonia in heart transplant patients.